Abbott, a global healthcare company, has obtained CE Mark approval for its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, designed to support daily diabetes management.
The FreeStyle Optium Neo system has a high contrast icon-driven display, sleek meter design, blood glucose trend indicators that visually notify patients when they are experiencing hypo- or hyperglycemic trends, and an insulin dose feature, which allows healthcare professionals to program a patient’s insulin plan into the meter.
Abbott Diabetes Care senior vice president Heather Mason noted the FreeStyle Optium Neo system is the company’s latest advance based on the innovative technology that is at the heart of both its precision and optium products.
"The device’s advanced design and technology enables the ability to track glucose trends and log insulin, which may help improve the patient’s daily diabetes management. This system is one more example of how Abbott is focused on meeting the needs of patients," Mason added.
The FreeStyle Optium Neo system, which is designed to be used with FreeStyle Optium blood glucose and ketone test strips, will be available in Europe in the coming weeks.